Tasly Pharmaceutical Group Co. Ltd. Class A

Tasly Pharmaceutical Group Co. Ltd. Class A

SSSE:600535
14.33
CNY
-0.06
(-0.42%)
0.77EPS
17.10P/E
20.92BMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.66
8.67
8.82
9.23
10.64
11.88
12.52
9.04
5.29
5.88
5.83
5.69
5.52
5.35
Basic EPS, GAAP
0.76
0.94
0.99
0.78
0.91
1.02
0.66
0.75
1.57
-0.18
0.72
0.64
0.74
0.82
Free Cash Flow per Basic Share
-0.32
-0.1
-0.27
0.42
-0.86
0.47
0.63
0.92
1.48
1.28
1.28
0.97
0.7
- -
Dividend per Share
0.17
0.42
0.42
0.41
0.61
0.57
0.6
0.53
0.41
0.38
0.38
0.7
0.42
0.31
Book Value per Share
2.67
3.35
4.94
5.26
5.72
6.96
7.36
7.91
8.58
8.28
8.25
7.97
8.3
8.65
Tangible Book Value per Share
2.16
2.78
4.29
4.55
4.94
5.81
6.07
6.82
7.4
7.21
6.89
6.6
6.89
7.28
Basic Weighted Avg Shares
1,450
1,451
1,500
1,511
1,513
1,515
1,517
1,501
1,502
1,468
1,488
1,493
1,493
1,494
Sales/Revenue/Turnover
11,108
12,578
13,228
13,945
16,094
17,990
18,998
13,576
7,952
8,637
8,674
8,498
8,236
7,999
Operating Margin (%)
14.42
15.8
15.53
12.26
13.51
13.62
10.52
11.3
16.5
15.81
17.35
17.59
17.66
22.49
Depreciation Expense
193
239
290
309
342
357
387
540
488
518
505
496
455
- -
Net Income, GAAP
1,098
1,368
1,479
1,176
1,377
1,545
1,001
1,126
2,359
-264
1,071
956
1,105
1,223
Effective Tax Rate (%)
17.77
16.31
15.14
18.52
19.25
18.61
24.62
25.2
11.6
- -
16.74
19.62
21.1
21.03
Profit Margin (%)
9.88
10.88
11.18
8.44
8.55
8.59
5.27
8.29
29.66
-3.06
12.35
11.24
13.42
15.29
Working Capital
737
1,022
3,311
3,017
3,709
9,303
7,886
6,302
7,394
7,113
6,363
4,961
5,922
6,402
LT Debt
869
812
798
400
892
5,156
3,232
1,133
1,116
1,452
1,496
322
268
145
Total Equity
4,178
5,068
7,707
8,207
8,974
11,208
11,864
12,384
13,314
12,678
12,690
12,111
12,548
13,043
Return on Invested Capital (%)
18.57
17.49
14.11
10.31
9.71
8.28
4.95
6.22
15.78
- -
6.7
5.89
7.63
8.39
Return on Capital (%)
18.85
18.91
15.92
11.56
11.23
9.98
6.58
7.79
15.66
- -
7.89
7.54
8.46
9.46
Return on Common Equity (%)
27.07
31.44
24.03
15.25
16.57
16.11
9.24
9.75
18.91
-2.08
8.64
7.87
9.09
9.67

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
907
360
37
LT Borrowings
202
153
111
LT Finance Leases
40
33
34
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,494
1,494
1,494
Market Capitalization
21,438
19,765
20,915

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,624
8,104
8,059
Cash, Cash Equivalents & STI
2,462
3,362
3,700
Accounts Receivable, Net
1,348
1,295
1,328
Inventories
1,443
1,458
1,383
Total Current Liabilities
2,321
1,670
1,657
Payables & Accruals
- -
- -
- -
ST Debt
907
360
37
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.28%
0.37%
3.6%
Free Cash Flow
-64.68%
-0.99%
-28.02%
Net Income, GAAP
-51.61%
-100.44%
15.63%
Sales/Revenue/Turnover
-2.78%
-7.5%
-3.08%
Total Cash Common Dividend
4.84%
2.91%
-39.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,049
2,323
2,091
2,036
8,498
2025
2,055
2,233
- -
1,926
8,236
2026
2,165
2,036
1,873
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.25
0.12
0.08
0.64
2025
0.21
0.31
- -
0.08
0.74
2026
0.25
0.35
0.14
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.34
0.01
0.34
0.7
2025
0.21
- -
- -
0.21
0.42
2026
- -
0.1
- -
- -
- -

Company Description

CEO
Jin Yong Cai
Full Time Employees
10,563
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 2 Pujihe East Road Tianjin TI China 300410
IPO Date
Aug 23, 2002
Website
tasly.com
Business
Tasly Pharmaceutical Group Co., Ltd (600535.SS) researches, develops, manufactures and sells traditional Chinese medicines, chemical preparations, biological products and health care items primarily in China and internationally. Founded in 1994 and headquartered in Tianjin, China, the company operates through segments including biopharmaceuticals, healthcare products and medical services, offering prescription drugs for cardiovascular and cerebrovascular conditions, hepato-biliary-pancreatic disorders, respiratory issues, diabetes, tumor immunity, gastrointestinal diseases, gynecology, rheumatism, neurology, pruritus and andrology; over-the-counter drugs; herbal medicines; chemical raw materials; pharmaceutical substances and APIs; herbal extracts; concentrated herbal granules; health supplements; and medical devices. Its flagship products feature flagship offerings like Danhong injection alongside a broad portfolio integrating traditional Chinese medicine with modern techniques, targeting domestic markets that account for the majority of revenue alongside growing international presence in regions including the United States. Recent developments include China Resources Sanjiu Medical's acquisition of a 28% stake valued at 6.212 billion yuan to expand in traditional Chinese medicine, alongside approvals for clinical trials of the stem cell therapy NR-20201 for acute ischemic stroke, strategic partnerships such as with Arfive for health product distribution in Henan, and investments in ventures like Hygieia Biotechnology.